Flirting with Fraud: Why Sextortion Is the Most Devastating Dating Scam
Sextortion has emerged as one of the most dangerous forms of romance scams, preying on online daters and, tragically, claiming the lives of teenagers. Fraudsters use fake profiles to lure victims into sharing intimate content, only to threaten exposure unless a ransom is paid. Regula, a global developer of identity verification (IDV) solutions, shares a vision of how social media and dating platforms can strengthen protections to safeguard users.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213790016/en/
Can you spot a romance scam? Scammers are getting smarter, using fake identities, AI, and emotional manipulation to exploit trust. See how these scams work and what can be done to stop them. (Graphic: Regula)
Romance scams come in many forms, exploiting trust and emotional vulnerability to defraud victims. Their common tactics include:
- Catfishing: Scammers create fake identities to build trust and manipulate victims.
- Military Scams: Fraudsters pose as deployed soldiers seeking financial assistance.
- Inheritance Scams: Victims are deceived with false claims of large inheritances requiring upfront fees.
- Pig-Butchering (Crypto Investment) Scams: Scammers feign romantic interest to lure victims into fraudulent investment schemes.
However, according to reports from leading child safety organizations, including the National Center for Missing and Exploited Children (NCMEC) and Thorn, sextortion is one of the most severe threats, with cases surging at an alarming rate. The FBI reported over 12,000 complaints in 2023 alone, resulting in millions in financial losses, severe psychological trauma, and, in some cases, even fatalities. Younger users and those new to online dating are particularly vulnerable.
Common sextortion tactics include:
- Fake Identities: Scammers pose as attractive singles, influencers, or even celebrities to build quick trust.
- Rapid Escalation: Conversations quickly shift from introductions to intimate exchanges.
- Blackmail Threats: Once explicit content is shared, scammers demand money, cryptocurrency, or further compromising images under the threat of exposure.
- AI-Driven Deception: Some scams leverage deepfake videos or AI-powered chatbots to manipulate victims.
The Role of Identity Verification in Preventing Sextortion
Sextortion thrives in environments where fake profiles and anonymity enable bad actors to operate freely. Social media and dating platforms play a critical role in combating this threat—through proactive moderation, AI-powered content monitoring, and user education. Stronger identity verification during registration is also a valuable tool in this arsenal, but it must be implemented thoughtfully, balancing fraud prevention with user privacy and accessibility.
Different online platforms use varying levels of verification, ranging from strongest to weakest:
- ID & Biometric Verification – Matching government-issued IDs with real-time selfies for authentication.
- Real-Time Selfies Without ID Validation – Confirming a live presence but without a verified identity document.
- Basic Checks – Verification through phone numbers, email, or linked social media accounts.
- Self-Reported Identity Without Validation – The least secure method, relying solely on user-provided information.
How Biometric and ID Verification Strengthens Security:
- Eliminating Fake Profiles: Biometric checks make it significantly harder for scammers to create fake accounts.
- Anti-Spoofing Technology: Prevents impersonation by detecting fraudulent attempts using photos or masks.
- Liveness Detection: Confirms a real person is present, preventing AI-generated deception.
“When faced with strong verification measures, scammers don’t simply disappear—they move to less secure platforms where they can continue their schemes unchecked. Standardizing biometric ID verification across multiple platforms would make it significantly harder for them to do so, creating a safer ecosystem across social media, dating apps, and other online services." – Jan Stepnov, Identity Verification Expert at Regula.
Empowering Users to Stay Safe
While platforms must take stronger security measures, users can also protect themselves by:
- Being Cautious of Fast-Moving Relationships: Avoid engaging in intimate exchanges early in conversations.
- Interacting with Verified Users: Prioritize connections with verified profiles.
- Reporting Suspicious Activity: Flagging blackmail attempts and scam behavior.
- Never Paying Ransoms: Complying with extortion often leads to further threats.
For more insights on how identity verification is transforming online dating security, visit Regula’s blog.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213790016/en/
Contacts
Kristina – ks@regulaforensics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release
Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release
Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom